Colorectal Cancer Management: Applying the Evidence to Optimize Screening and Treatment

Colorectal cancer (CRC) is the third most common tumor type in men and women in the United States. Screening is important to reduce mortality because it allows for detection of CRC at earlier stages when the disease is usually asymptomatic and when it is most curable. Given the urgent need for early detection, the Veterans Health Administration (VHA), the largest integrated healthcare provider in the United States, maintains that all eligible veterans at average or high risk for CRC should be offered screening. However, overall, only 39% of patients have their CRC detected at early localized stages, when 5-year survival is approximately 90%. Moreover, there continues to be a need for improved treatment approaches in the metastatic setting. In recent years, advances in the understanding of tumor biology have resulted in the development and application of new treatment strategies, particularly in advanced disease settings.

This case-based program will evaluate current and emerging methods to optimize CRC screening and the management of patients with metastatic disease. Additionally, the evolving role of targeted therapies and the use of biomarkers in the management of metastatic CRC will be discussed.

Available until August 24, 2011, this activity offers:
Physicians: 1.25 AMA PRA Category 1 Credits^™
Nurses: 1.2 contact hours

This activity is jointly sponsored by SCEPTER^™ and Quintiles Medical Education. This activity is co-provided by Global Education Group and SCEPTER^™.